ORIC Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

ORIC Pharmaceuticals şirketinin kazançları yıllık ortalama -19.1% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında arttı.

Anahtar bilgiler

-19.1%

Kazanç büyüme oranı

45.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-43.7%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Gelir ve Gider Dağılımı

ORIC Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:4TZ Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	-120	28	107
30 Jun 24	-111	27	98
31 Mar 24	-102	26	88
31 Dec 23	-101	26	85
30 Sep 23	-93	24	77
30 Jun 23	-93	24	69
31 Mar 23	-90	25	64
31 Dec 22	-89	25	62
30 Sep 22	-91	25	62
30 Jun 22	-85	25	60
31 Mar 22	-85	24	62
31 Dec 21	-79	22	57
30 Sep 21	-84	20	52
30 Jun 21	-91	18	48
31 Mar 21	-81	16	40
31 Dec 20	-74	13	36
30 Sep 20	-54	11	31
30 Jun 20	-35	9	28
31 Mar 20	-30	7	25
31 Dec 19	-27	6	23
31 Dec 18	-21	3	19

Kaliteli Kazançlar: 4TZ şu anda kârlı değil.

Büyüyen Kar Marjı: 4TZ şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4TZ kârlı değildir ve zararlar son 5 yılda yılda 19.1% oranında artmıştır.

Büyüme Hızlandırma: 4TZ 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4TZ kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4TZ hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -43.75% ) sahiptir.

ORIC Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

President recently bought €1.2m worth of stock

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

ORIC Pharmaceuticals, Inc. Provides Corporate Update

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

New 90-day high: €30.20

New 90-day high: €22.80

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: €17.00

ORIC Pharmaceuticals, Inc. announced that it expects to receive funding from a group of investors

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin